|
1）White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med. 2010; 182: 396-403
|
|
|
|
2）Yao JC, Shah MH, Ito T, et al; RAD001 in Advanced Neuroendocrine Tumors, Third Trial （RADIANT-3） Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364: 514-23
|
|
|
|
|
|
3）Doi T, Muro K, Boku N, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol. 2010; 28: 1904-10
|
|
|
|
|
|
4）Yoon DH, Ryu MH, Park YS, et al. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer. 2012; 106: 1039-44
|
|
|
|
|
|
5）Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009; 27: 2630-7
|
|
|
|
|
|
6） Ellard SL, Clemons M, Gelmon KA, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer. J Clin Oncol. 2009; 27:4536-41
|
|
|
|
|
|
7）Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012; 366:520-9
|
|
|
|
|
|
8）ノバルティスファーマ．アフィニトール®錠 特定使用成績調査における間質性肺疾患の有害事象についての集計結果．http://product.novartis.co.jp/afi/ts/pms_kanshitsusei_20120116.pdf
|
|
|
|
|
|
9）Maroto JP, Hudes G, Dutcher JP, et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol. 2011; 29: 1750-6
|
|
|
|
|
|
10）Mizuno R, Asano K, Mikami S, et al. Patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol. 2012; 42: 442-6
|
|
|
|
|
11）Akata K, Yatera K, Ishimoto H, et al. Two cases of everolimus-associated interstitial pneumonia in patients with renal cell carcinoma. Intern Med. 2011; 50: 3013-7
|
|
|
|
|
12）Errasti P, Izquierdo D, Martin P, et al. Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience. Transplant Proc. 2010; 42: 3053-4
|
|
|
|
|
|
13）Carreño CA, Gadea M. Case report of a kidney transplant recipient converted to everolimus due to malignancy: resolution of bronchiolitis obliterans organizing pneumonia without everolimus discontinuation. Transplant Proc. 2007; 39: 594-5
|
|
|
|
|
|
14）Exposito V, de Prada JA, Gomez-Roman JJ, et al. Everolimus-related pulmonary toxicity in heart transplant recipients. J Heart Lung Transplant. 2008; 27: 797-800
|
|
|
|
|
|
15）Alexandru S, Ortiz A, Baldovi S, et al. Severe everolimus-associated pneumonitis in a renal transplant recipient. Nephrol Dial Transplant. 2008; 23: 3353-5
|
|
|
|
|
|
16）O’Donnell A, Faivre S, Burris HA 3rd, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 2008; 26: 1588-95
|
|
|
|
|
|
17）Schrader J, Sterneck M, Klose H, et al. Everolimus-induced pneumonitis: report of the first case in a liver transplant recipient and review of treatment options. Transpl Int. 2010; 23: 110-3
|
|
|
|
|
|
18）Vandewiele B, Vandecasteele SJ, Vanwalleghem L, et al. Diffuse alveolar hemorrhage induced by everolimus. Chest. 2010; 137: 456-9
|
|
|
|
|
|
19）Depuydt P, Nollet J, Benoit D, et al. Fatal acute pulmonary injury associated with everolimus. Ann Pharmacother. 2012; 46: e7
|
|
|
|
|
|
20）ノバルティスファーマ．アフィニトール®錠．市販直後調査開始から現在までの副作用収集状況，http://product.novartis.co.jp/afi/document/
|
|
|
|
|
|
21）Endo M, Johkoh T, Kimura K, et al. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer. 2006; 52: 135-40
|
|
|
|
|
|
22）White DA, Schwartz LH, Dimitrijevic S, et al. Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus （RAD001）. J Thorac Oncol. 2009; 4: 1357-63
|
|
|
|
|
|
23）ノバルティスファーマ．アフィニトール®適正使用ガイド．http://product.novartis.co.jp/afi/document/
|
|
|
|
|
|
24）Malouf MA, Hopkins P, Snell G, et al. An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. Respirology. 2011; 16: 776-83
|
|
|
|
|